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doi:10.1016/j.ejvs.2009.05.019Abstract Background: Endothelial progenitor cells (EPC) are a subpopulation of bone-
marrow mononuclear cells that are capable of generating new blood vessels in areas of
ischaemia or infarction. This review examines the regenerative potential of EPC to ameliorate
peripheral ischaemia.
Methods: An online search was done using OVID Medline Search, PubMed, and Cochrane Review
Database, for all reviews and original articles in English concerning progenitor or bone-marrow
mononuclear cells.
Results and conclusion: There are many controversies in EPC research, especially in the areas
of identification, characterization, and therapeutic use. Both animal and human studies have
shown benefits from using EPC to combat peripheral arterial and cerebrovascular disease. To
bring EPC into wider clinical use, larger controlled clinical trials and better methods of aug-
menting EPC function and lifespan are required. Until then EPC should be used under robust
trial conditions with ethical approval.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Successes with stem cell therapies in the treatment of
haematological disorders over the past four decades,
coupled with developments in our understanding of the
physiology of vascular remodelling, have fuelled much
interest in regenerative medicine and therapeutic restora-
tion of the damaged organ. The classical theory of0) 1133922628; fax: þ44 (0)
H.R.S. Girn).
ty for Vascular Surgery. Publishevasculogenesis postulates that the adult vascular tree is
formed during foetal development, and vascular repair in
the adult occurs by mitotic division and migration of mature
endothelial cells from pre-existing blood vessels. Develop-
ments over the last decade or so, however, suggest that
postnatal vasculogenesis (called neoangiogenesis) is
brought about by circulating progenitor cells, capable of
differentiating into mature blood vessel endothelial cells.1
One of the breakthroughs came in 1997 when Asahara
et al. isolated cells in the peripheral blood that were
capable of differentiating into mature endothelial cells
in vitro.1 They also showed in vivo mobilization and incor-
poration of these autologous cells into sites of tissued by Elsevier Ltd. All rights reserved.
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ischaemia model. This was the first step in identification of
the endothelial progenitor cells (EPC) and confirmed that
adult neoangiogenesis was different from embryonic vas-
culogenesis in that it did not rely exclusively on the division
of native endothelial cells in the blood vessels.
The term progenitor refers to a population of stem cells
that remain in a state of growth arrest in the body while
retaining the capacity to enter cell cycle on demand and
differentiate into progeny. Progenitor cells are different
from stem cells in their inability to renew themselves
indefinitely. Therefore they are believed to becomeobsolete
after a limited number of cell divisions and seem to lose their
proliferative potential with maturity, with the highest
proliferative potential found in cells derived from umbilical
cord blood compared to peripheral blood in humans.2
Bone marrow is believed to be the major site of origin of EPC
e bone-marrow-derived cells (BMDC) e but recent reports
suggest that EPC can be derived from other sources such as
liver, epicardium and intestine, and non-BMDC are probably
more important in the setting of postnatal vasculogenesis.
EPC in general facilitate neovascularization by trans-
locating to sites of vascular ischaemia, differentiating into
endothelial cells, and increasing collateralization. They
have been shown in ex vivo cultures to form three dimen-
sional tubular structures (neoangiogenesis) that could
rescue tissue from ischaemia, and preserve function by
physical limitation of the infarct zone.3
The majority of translational work investigating the
therapeutic potential of EPC has been related to myocar-
dial diseases e coronary artery disease (CAD), chronic left
ventricular dysfunction and ischaemic cardiomyopathy e
with some evidence also emerging from peripheral arterial
disease (PAD). Furthermore, the adjuvant potential of the
EPC as a cardiovascular risk biomarker has been suggested,
based on the inverse correlation between the number and
migratory activity of EPC with risk factors for CAD,
including diabetes mellitus (DM),4 hypercholesterolaemia,5
cigarette smoking,6 age7 and hypertension.8 This review
examines the relevant physiology of the EPC for a clinician
and provides an insight into the evidence behind the
potential of EPC therapy to combat peripheral ischaemia.Methods
An online search was done using OVID Medline Search,
PubMed, and Cochrane Review Database from January 1997
to August 2008, for all articles in English using keywords
endothelial progenitor cells, circulating or bone-marrow-
derived progenitor cells, neoangiogenesis. The clinical
trials were searched separately for each disease process by
meshing keywords peripheral arterial disease, coronary
artery disease and stroke with endothelial progenitor cells.
All the abstracts were reviewed by at least 2 reviewers and
409 articles shortlisted for detailed study, of which 49 were
included in this paper. Articles included were those
detailing clinical trials and translational research investi-
gating the potential of bone marrow or circulating EPC for
neovascularization. For clinical studies, only papers
relating to human trials in atherosclerosis were selected.
This was the only criterion used for exclusion of clinicaltrials because a meta-analysis is not attempted, given the
diversity of protocols and outcomes present. In case of
disagreement between the first three authors, the senior
author (SHV) made the final decision. SHV independently
reviewed the collected data for consistency and relevance.
Problems with Characterization and
Quantification of EPC e Impact on Clinical
Application
At present there is no single best approach to characterize
or quantify EPC. This problem is well recognized and arises
from a combination of issues. There are various sub-cate-
gories of stem cells such as haematopoietic stem cells
(HSC), EPC, epithelial cell lines, cancer stem cells, neural
stem cells and very small embryonic-like stem cells (VSEL).
These cell lines share a variety of cell-surface markers and
the markers tend to change in accordance with the devel-
opmental hierarchy of stem cells: embryonic stem cells
have different surface markers as compared to differenti-
ated cells higher up the chain.
The source of an EPC influences the identifying markers.
Cardiac muscle, adipose tissue, liver and intestinal tissues,
as potential sources of extractable cells with EPC charac-
teristics,9,10 often have their own identifying markers.
These labels are useful for identifying cells from specific
anatomical ‘niches’ in the peripheral blood but may
contribute to inaccuracies in the estimation of the cumu-
lative effect of stem cell therapies; the calculation of
the number of circulating EPC in healthy versus diseased
individuals may also be misleading.
While no single cell-surface marker has been found to be
absolutely specific for EPC, there are several markers which
clearly identify functional EPC populations. These include
CD34 and vascular endothelial growth factor receptor-2
(VEGFR-2) and vascular endothelial cadherin. These
markers are found on mature endothelial cells as well and
so may lead to inclusion of a more mixed cell population
including mature cells with a lower proliferative capacity.
They have also been found to include cell populations that
participate in angiogenesis but do not differentiate into
endothelial cells in vitro. These cells, expressing blood
monocyte markers CD14 and CD45, are thought to facilitate
neoangiogenesis through secretion of angiogenic factors
(paracrine effect).11 The inclusion of mature and non-EPC
phenotypes may mask the potency of progenitor cell
therapy. For this reason, markers with a higher specificity
for immature cell-types such as CD133 may be helpful. At
present the best approach to quantify and characterize EPC
appears to be to include as many markers as possible.
As previously stated, EPC tend to lose their proliferative
potential as they mature, with the highest proliferative
potential being found in cells from umbilical cord blood.
Different cell-surface markers are associated with different
stages of maturation of EPC in their natural cell cycle:
immature EPC express cell-surface markers that closely
resemble HSC such as CD133. These markers are gradually
succeeded by a more endothelial phenotype, expressing
CD31, vascular endothelial cadherin and von Willlebrand
factor.2 This problem is further compounded by the ability
of cells of one lineage to differentiate into other cell
Stem Cell Therapy in PAD 477lineagese transdifferentiation. It is primarily the peripheral
blood mononuclear cells (PBMNC) that have been shown to
differentiate into endothelial as well as cardiac and neural
phenotypes in different culture media in vitro.12 No studies
have yet demonstrated progenitor cells with a specific
endothelial phenotype to be capable of differentiating into
alternate lineages. The similarities in phenotype and over-
lap in function of PBMNC may be explained by a common
stem cell population for EPC, HSC, and other progenitor
cells. EPC can thus be considered a differentiated form of
this primary progenitor cell with the greatest propensity for
further maturation into endothelial cells. It is as yet unclear
to what extent each progenitor cell is committed to its
mature counterpart, but it is likely that potential for
transdifferentiation into alternate lineages exists in
immature EPC or embryonic stem cells, which are lower in
the maturation hierarchy.
The other important aspect of EPC therapy is to char-
acterize the angiogenic capacity of EPC. The three most
commonly used techniques for this purpose include: the
murine hindlimb ischaemia13 for in vivo animal studies,
maigel tube formation assays for estimating ex vivo angio-
genic potential by measuring the EPC capacity to form
three-dimensional structures (tube formation), and ex vivo
migration assays for estimation of migratory capacity.14
Although the ability of EPC to stimulate neoangiogenesis
seems apparent, different pre-clinical studies base their
results on different aspects of EPC function, making colla-
tive analysis of the data difficult. Similarly there have
always been suspicions about the actual impact of incor-
poration of EPC-derived endothelial cells into neovessels,
and it now seems more likely that the paracrine effects of
EPC therapy play a major role in neoangiogenesis. EPC
numbers and function are augmented by a variety of growth
factors such as VEGF,15 stromal-derived factor-1,16 insulin-
like growth factor-1,17 hepatocyte growth factor18 and
thymosin b4,19 which also encourage adjacent endothelial
cells to stimulate angiogenesis. Another confounding factor
is the use of gene therapy20 to enhance functional potency
of EPC and growth factor therapy21 by reducing the
requirement of bone marrow for ex vivo expansion of EPC
prior to inoculation or transplantation. These therapies
have their own paracrine effect and this may again lead to
inaccuracies in estimating the actual impact of EPC on the
observed functional outcome.
Relationship of EPC to Cardiovascular Risk
Factors
Cardiovascular risk factors impair the function of EPC by
age-related exhaustion of the bone-marrow niche and by
EPC senescence. EPC senescence is a term used to describe
progenitor cells which have lost their ability to proliferate,
migrate and differentiate into mature cells. Therefore,
senescence accounts for reduced EPC function and
numbers. The number and migratory activity of EPC have
been reported to be reduced in most of the major cardio-
vascular risk factors such as DM, hypertension, hyper-
cholesterolaemia,5 increasing age,22 and cigarette
smoking.6 Most likely, the observed impairment of EPC in
patients with cumulative cardiovascular risk factors isattributable to their reduced regenerative capacity. These
results have been confirmed in the ‘Endothelial Progenitor
Cells in Coronary Artery Disease’ (EPCAD) study, which
demonstrated that the level of circulating CD34þ/KDRþ
EPC predicts the occurrence of cardiovascular events and
cardiovascular death.23 In patients with arterial hyperten-
sion, systolic blood pressure inversely correlates with the
number of circulating CD133þ and CD34þ/KDRþ EPC but
the number of colony-forming units is not impaired by
arterial hypertension. Impaired EPC activity in hypertensive
patients is proposed to occur via angiotensin II-mediated
acceleration of EPC senescence and angiotensin II type 1
receptor antagonists such as valsartan increasing the
number of regenerating EPC.
In vitro studies have demonstrated that culture media
conditioned by EPC from patients with Type 1 DM exhibit
reduced angiogenic capacity and a reduced capacity to
participate in tubule formation. The number of EPC has also
been shown to correlate inversely with Hb A1c levels,
providing an insight into the relation between tight glucose
control and EPC function.24
Similarly, it has been demonstrated that blood choles-
terol level is inversely correlated to EPC number and
function. Oxidized low-density lipoproteins (LDLs) have
been shown to impair the proliferative, migratory, adhesive
and in vitro vasculogenic capacity of EPC with a dose-
dependent effect. One of the explanations for this effect is
the inhibition of VEGF-induced EPC differentiation through
the dephosphorylation of Akt (a protein kinase) by oxidized
LDLs.25 This is important clinically as statins act by mobi-
lizing bone-marrow-derived EPC via the Akt pathway,
resulting in increased numbers of EPC with enhanced
functional activity and migration capacity.26
Non-pharmacologic interventions such as physical exer-
cise have been reported to significantly increase number
and function of circulating EPC in patients who resumed
a standardized physical activity during a rehabilitation
programme, in patients with coronary artery disease (CAD)
and PAD, and in healthy individuals exercising for
30 min,27 possibly via a VEGF-dependent mechanism.
Patients with CAD have a number of identifiable risk
factors which have an inverse correlation with EPC senes-
cence.28 This relationship illustrates the role of EPC in
cardiovascular pathophysiology, and highlights the poten-
tial of EPC as adjuvant biomarkers in arterial disease, but
the problems with characterization and identification of
EPC need to be resolved before this potential can be real-
ized in a clinical setting.Role of EPC in Myocardial Ischaemia
The majority of work investigating the role of EPC has been
related to myocardial disease, including acute myocardial
infarction (AMI), CAD, chronic left ventricular dysfunction
and ischaemic cardiomyopathy. To date, over 20 random-
ized human trials investigating the role of EPC in myocar-
dial disease have been published, with a number of trials
currently actively recruiting. However, meta-analysis of
these trials is not feasible because of varying protocols,
dose regimens, patient populations and randomization
criteria used.
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investigating the potential of progenitor cell therapy in
AMI.29 19 patients with reperfused AMI were randomly
assigned to receive an intracoronary (into the infarcted
artery) infusion of either autologous BMDC or circulating-
blood-derived progenitor cells into the infarct artery with
11 patients in the control group. Best medical therapy was
given to all patients. At 4 months an increase in left
ventricular ejection fraction (LVEF), improved regional wall
motion in the infarct zone, reduced end systolic left
ventricular volumes and increased myocardial viability in
the infarct zone were reported, compared with the control
group. No differences were detected between the periph-
eral blood-derived progenitor cells and BMDC groups and no
adverse reactions were reported.29 Although this trial
established feasibility of progenitor cell therapy, it did not
establish the beneficial role of any one specific cell lineage.
It is not certain that endothelial cell incorporation leading
to neoangiogenesis was responsible for the improvement
noted. 25% of the patients in the cell therapy group had re-
stenosis of the stented lesion although new collaterals at
these sites were observed and no comparative information
is available for the control group. This trial eventually
recruited 59 patients in the progenitor cell therapy group
and has recently reported sustained improvement in
cardiac function at 5 years with no long-term side effects.30
The BOOST study investigated the effect of an injection
of autologous unfractionated BMDC in patients post MI.31 60
patients were randomized to treatment versus control
(optimum post infarction medical treatment only) with 30
in each group. At 6 months it was demonstrated that the
LVEF was 6% higher in the BMDC-infused patients than in the
control group and there was associated improvement in
systolic wall motion. However these improvements were
not sustained at 18 months.
The largest and most recent trial to date is the REPAIR-
AMI that investigated the effect of infusion of basement-
membrane-derived mononuclear cells post-AMI.32 199
patients were recruited to the trial and allocated by double
blind randomization to receive mononuclear cells or
placebo. 101 patients received infusion of mononuclear
cells; 98 patients received placebo. At 4 months the
treatment group demonstrated a moderate improvement in
LVEF, (5.5% versus 3% in the control group, pZ 0.01) which
was sustained at one year.
The role of EPC in relation to cardiomyopathy and
chronic left ventricular dysfunction has also been investi-
gated. Two small published trials (23 patients and 27
patients) have investigated the effect of an infusion of
autologous mononuclear cells on patients with ischaemic
cardiomyopathy.33 Both of these trials are non-randomized
and give limited evidence relating to the potential benefit
of progenitor cells in heart failure, but they do suggest an
improved treadmill performance following injection. The
‘Progenitor Cell Therapy in Dilative Cardiomyopathy’ study
is currently recruiting to establish the effect of an intra-
coronary infusion of bone-marrow-derived mononuclear
cells (BMMNC) on cardiovascular function in patients with
established cardiomyopathy.34
The TOPCARE-CHD registry,35,36 involving 121 consecutive
patientswithanMI in theprevious3monthsandpooled results
from the TOPCARE-CHD pilot and crossover trial, showed thatN-terminal pro-atrial natriuretic peptide (NT-proANP) and N-
terminal pro-brain natriuretic peptide (NT-proBNP) serum
levels were reduced 3 months after transcoronary adminis-
tration of BMDC. In this study, colony-forming capacity was
used as a measure of the functional capacity of the adminis-
tered cells as described previously. The results also demon-
strated that patients receiving a higher proportion of colony-
forming cells had significantly lower cardiac mortality rates
than those receiving a lower proportion.36
A generous body of translational evidence now exists
supporting the potential of progenitor cell therapy in
cardiology. The most common method of progenitor cell
procurement appears to be autologous transplantation of ex
vivo expanded BMMNC. This consists of a heterogenous
suspension of progenitor cells with varying proportions of
CD34/CD45/CD133 positive cells. It has not been possible to
decide the exact mechanisms responsible for the observed
benefits with this therapy e direct cellular effect or
paracrine effect. Some protocols also include G-CSF pre-
treatment for more robust and viable progenitor cell harvest
as these agents facilitate mobilization of HSC and EPC into
the peripheral blood.37 These agents are pro-coagulant and
pro-inflammatory and can induce angina themselves. Since
these agents have a strong pro-angiogenic affect of their
own, via mediation of VGEF and similar peptides, the
beneficial affect attributed to EPC/progenitor cells may
actually be due to the paracrine affect of G-CSF.The Role of EPC in Peripheral Ischaemia
Extrapolation of evidence from animal studies to human
studies relating to the feasibility of autologous progenitor
cell transplantation in limb ischaemia is limited. In the
‘Therapeutic Angiogenesis using Cell Transplantation’
(TACT) study (2002),38 115 patients (74 limbs PAD and 41
limbs thromboangiitis obliterans) were randomly assigned
to injection of autologous BMMNC or placebo PBMNC into
the gastrocnemius muscle of the affected limb. At 4
weeks, those legs into which BMNC had been injected had
improved ankle-brachial pressure index (ABPI), improved
transcutaneous oxygen pressure, reduced rest pain
and increased pain-free walking time. These improve-
ments were sustained at 24 weeks without serious
complications.
Recently the long-term results of this trial have been
published.39 These demonstrated a 3-year amputation-free
rate of 60% (95% CI 46e74) in PAD (Fontaine stage III and IV)
and 91% (95% CI 82e100) in patients with thromboangiitis
obliterans in the intervention limb. ABPI did not change
significantly during the 2-year follow-up period in either
group of patients. Pain scale and ulcer size were, however,
improved significantly (p< 0.001). Similar to cardiac studies,
delineation of the specific mechanism of effect is lacking;
improvement is attributed to the neoangiogenesis promoted
by the BMMNC which contain EPC fractions and their associ-
ated paracrine effect. These factors possibly augment the
local angiogenic effect of ischaemia itself but evidence of
transdifferentiation of progenitor cell lineages is lacking. It is
also difficult to interpret these results as no control data are
presented and therefore no conclusion can be made
regarding long-term comparative effects of treatment.
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et al.40 and Saigawa et al.41 reported encouraging results
using similar protocols in their randomized studies including
small numbers of patients. Lenk et al. were able to achieve
a similar beneficial effect with intra-arterial infusion of
PBMNC (harvested following priming with G-CSF) in 7
patients with infrapopliteal PAD and critical ischaemia.42
They reported no side effects with G-CSF stimulation of
intra-arterial infusion and noted a thirty-fold improvement
in pain-free walking distance and a concomitant improve-
ment in ABPI at 12 weeks. There were no controls studied in
this group.
Ishida et al. conducted a similar study usingG-CSF therapy
for 5 days prior to PBMNC including CD34þ cell harvesting and
intramuscular injection into the ischaemic limbs.21 This was
a small study in 6 patients (5 thromboangiitis obliterans and 1
critical ischaemia) but some encouraging results have been
reported. ABPI improvement associatedwith a 300% increase
in pain-free walking and 200% increase in total walking
distance was noted at 4 weeks post-therapy and results were
sustained at 6 months. A variable degree of pain relief was
achieved at 10 days but, more importantly, ulcer healing
was noted in all three patients with ulcers. This group has
reported cell therapy as an alternative to angioplasty but
given the nature of this study it would be optimistic at this
stage. However, they were able to repeat the treatment in 2
patients where ulcers recurred at 1 year. Again, it is unjus-
tified to pin down the benefit to EPC alone. Similar results
following PBMNC transplant post-G-CSF priming into 92
ischaemic limbs has been reported by Kawamura et al. in
a slightly different population of PAD.43 68 of the 92 patients
treated were on haemodialysis for chronic renal failure. But
some of the patients in Fontaine I and II classes have also
been classified as critically ischaemic in this study. The
total amputation rate was very high (64%) in Fontaine IV
group (53/92), which is the group likely to gain most benefit
from such treatment.
While most of the studies have reported favourable
results, some important insights can be gained from the
study reported by Miyamoto et al.44 BMMNC harvested from
the iliac crest were injected in 11 ischaemic limbs of 8
patients with thromboangiitis obliterans. No G-CSF priming
was done. Initial improvement on a visual analogue scale
was noted in all patients and ulcers healed completely in
88% cases. However, 50% of cases experienced adverse
affects on follow-up: 1 case of sudden death of unknown
origin in a 30-year-old without any previous cardiac history
at 20 months, AV fistula formation at 7 months in 1 patient,
and 2 patients with worsening symptoms. The initial report
of the TACT study also reported 2 sudden deaths out of 25
people treated, within 24 weeks, but the population in the
TACT study was much older compared to this study. An
association has also been noted between unstable angina
and the intra-plaque presence of angiogenic peptides in
animal studies; it has therefore been suggested that these
agents might play a role in plaque progression and insta-
bility.45 The biological activity of most of the angiogenesis
agents currently being tested clinically are highly potent,
and it is likely that this could cause unwanted neo-
vascularization in non-targeted tissues such as in patients
with diabetic retinopathy who have been found to have
increased numbers of receptors for VEGF.46There are several current trials, the results of which are
awaited, but clearly the importance of long-term follow-up
in patients undergoing cell therapy cannot be
underestimated.
Role of EPC in Cerebrovascular Disease
The role of EPC in cerebrovascular ischaemia is currently
under investigation but there a paucity of data from human
studies. The vast majority of studies on the effects of EPC
on outcomes after cerebral ischaemia have been conducted
in mice and in ischaemic stroke following medium and large
vessel disease. While these studies have shown positive
outcomes, there is currently no consensus on which EPC cell
type is optimal or the optimal timing for the administration
of stem cell therapies post-stroke. However, EPC adminis-
tration has been shown to improve clinical outcomes after
an ischaemic stroke in animal models47 and EPC levels have
been shown to be of prognostic value in human studies. Low
levels of circulating CD34þ EPC are strongly predictive of
severe neurological impairment (day 2) and adverse clinical
outcomes (day 90) following an ischaemic stroke.48
The exact mechanism of action of EPC in the brain is
poorly understood. There is some evidence that PBMNC are
capable of differentiating into neural cells and are thus
theoretically capable of structural regeneration12 but most
in vivo studies of peripheral or cord-blood-derived EPC
demonstrate relatively few cells incorporated into ischae-
mic tissue.49 The disproportionately large improvement in
clinical outcome in mice treated with stem cell therapies
post-stroke compared to the actual number of stem cells
incorporated into ischaemic brain tissue indicate that the
restorative effect of these therapies is not entirely due to
transplanted cells. It is most likely the paracrine affect of
EPC which results in the reorganisation of nerve fibres in
the injured brain. This augments neuroplasticity and thus
improves long-term clinical outcomes in treated animals.
Conclusion
The holy grail of stem cell research is to develop the
capability of isolating specific progenitors from a donor
source, which can then be expanded ex vivo prior to
transplantation, within the time-frame of an emergent
situation such as a stroke, myocardial infarction or acute/
critical limb ischaemia, where the benefit achieved is most
likely to be greatest. But before this stage is reached there
are some critical issues which hinder the translation of cell
therapeutics. One of the problems is lack of standardization
in classification and characterization of donor cells and our
inability to track migration and differentiation of these
cells in vivo after an intervention has been carried out. This
has serious implications for quality control of transplant-
able cells and indeed for the safety of clinical trials. There
is a definite gap between what is known about specific EPC
subpopulations from experimental in vitro studies and
clinical trials, which use largely unfractioned BMMNC or
PBMNC samples because of the scarcity of EPC in any one
anatomical niche. This leads to difficulties in determining
the mechanism of action of these cell therapies in clinical
practice and the relative efficacy of EPC subpopulations
480 A.J. Devanesan et al.alone. Furthermore, current evidence suggests that the
paracrine effect of growth factors secreted by these cells
plays a more significant role than previously thought. With
our present level of understanding it is not possible to
refute the suggestion that cell therapies may merely be
augmenting hypoxia- or ischaemia-induced angiogenesis.
To date the evidence of the efficacy of EPC administration
in PAD is limited and the isolated impact of EPC remains
undetermined. PBMNC or BMMNC therapies seem to have
a beneficial effect in the short term, but long-term efficacy
and safety is still undetermined. Trials so far have largely
been limited to small uncontrolled or poorly randomized
studies. Although a beneficial effect is observed, the
mechanism of this effect seems to be different from the one
postulated by animal and in vitro studies. There is an
imminent need to set up a regulatory body to control the
quality of future trials by standardizing dosage, route and
type of cells to be transplanted, and all patients should have
a long-term follow-up for safety issues as mechanisms for
regulating uncontrolled cell division once injected are not
available. Specific trials are also required for G-CSF therapy
versus G-CSF-primed EPC therapy before the beneficial
effect canbe attributed to EPC. This paradigmwill take some
time to resolve and until then clinicians should view the
available data with an open but critical mind.
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